MDS Pharma Services Expands Drug Development and Manufacturing Capabilities Through Services Alliance with Patheon

December 17, 2002 - MDS Pharma Services has entered into a services alliance with Patheon Inc. (TSX: PTI) to provide the full range of early development, clinical and manufacturing services to the pharmaceutical and biotechnology industries.

MDS Pharma Services Advances Bioanalysis Capabilities with Watson™ LIMS on Citrix® Metaframe™ Server

October 28, 2002 - MDS Pharma Services is the first CRO to offer Watson-Citrix combination.

MDS Pharma Services Strengthens Bioanalytical Capabilities in Europe

October 23, 2002 - MDS Pharma Services has relocated and expanded its bioanalytical facility in Zurich, Switzerland, significantly enhancing the company's bioanalytical capabilities in Europe.

MDS Pharma Services Expands Early Clinical Research Facility in Phoenix, Arizona

October 3, 2002 - This new facility further extends our industry-leading capacity in early clinical research, which is currently nearly 800 beds, while allowing greater flexibility and study conduct capabilities.

New Small Molecule Development Program Offered by MDS Pharma Services

June 12, 2002 - Small Molecule Development Program is the latest innovation in our long-standing tradition of providing integrated drug development services.

MDS Pharma Services' Central Clinical Lab in Beijing First Lab in China To Receive College of American Pathologists' (CAP) Accreditation

June 7, 2002 - MDS Pharma Services has received accreditation from the College of American Pathologists (CAP) for its central clinical laboratory in Beijing, China.

MDS Pharma Services Expands Early Clinical Research Facility in New Jersey As Part of Global Expansion Plans

May 8, 2002 - MDS Pharma Services has expanded and relocated its early clinical research facility in Neptune, New Jersey, more than doubling its capacity for early clinical research studies.

MDS Pharma Services Enters Into Multi-Year, Global Agreement With AstraZeneca To Provide Customized Pharmacology Screening

April 23, 2002 - This contract makes MDS Pharma Services the exclusive provider of customized selectivity screen designed to address the adverse events potential of AstraZeneca compounds in the early research phase.

MDS Pharma Services Introduces Integrated 'Metabolism Resource' Service

April 22, 2002 - Metabolism Resource merges our superior expertise, experience and capacity, comprehensive range of metabolism services, and state-of-the-art technology with an integrated team approach.

MDS Pharma Services Establishes Drug Development Programs Capability

April 17, 2002 - Drug Development Programs service, incorporates a focused group of MDS Pharma Services' senior scientific consultants who are responsible for driving the implementation of each client's drug development plan, utilizing the full spectrum of the company's laboratory and clinical services.

MDS Pharma Services Expands Capabilities at Early Clinical Research Facility in Hamburg

March 19, 2002 - MDS Pharma Services has relocated its early clinical research facility in Hamburg, Germany, and expanded its capacity from 24 to 62 beds, improving accommodations for study participants while offering the latest clinical and study conduct capabilities.

DrugMatrix Development Milestone Announced by MDS Pharma Services and Iconix

February 25, 2002 - MDS Pharma Services Inc. and Iconix Pharmaceuticals Inc. announce achievement in product development for the commercial launch of DrugMatrix™.

MDS Pharma Services Announces Global Expansion Plans for 2002

February 13, 2002 - Expansion plans for 2002 at numerous sites worldwide, designed to strengthen the company's capacity to serve as a drug discovery and development partner.